Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for brain bleed: smarter use of a common drug may prevent worsening

NCT ID NCT07365150

Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug tranexamic acid can prevent brain bleed expansion in people with a type of stroke called intracerebral hemorrhage. The researchers are using new criteria to select patients most likely to benefit, based on bleed location and size. About 70 adults will be enrolled within 6 hours of symptoms. The goal is to see if this approach reduces early neurological worsening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primary ICH Diagnosis * Age ≥ 18 years * Within 6 hours of ICH * Supratentorial ICH * GCS ≥8 * Location-specific volume criteria (\>7ml for thalamus or internal capsule; \>30ml for putamen or lobar) Exclusion Criteria: * Severe pre-morbid disability (Pre-morbid modified Rankin scale 5) * Anticipated surgical treatment * Recent acute atherosclerotic cardiovascular diseases (e.g. acute coronary syndrome, ischemic stroke) * Receiving anticoagulation * Recent intravascular stent placement and on dual antiplatelet treatment * Expected life expectancy of \<1 year * Inability to participate in follow-up activity * Bleeding tendency * Severe renal impairment * Severe liver impairment * Known contraindication or allergy to tranexamic acid

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracerebral hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracerebral hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pamela Youde Nethersole Eastern Hospital

    NOT_YET_RECRUITING

    Hong Kong, Hong Kong

  • Prince of Wales Hospital

    RECRUITING

    Hong Kong, Hong Kong

  • The University of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.